Andrew Kuykendall, MD | Authors


Fedratinib Re-emerges as FDA-Approved Treatment of Myelofibrosis

October 17, 2019

Andrew Kuykendall, MD, discusses the background to the JAK2 inhibitor fedratinib (Inrebic), which was approved by the FDA in August 2019 for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis, including post–polycythemia vera or post–essential thrombocythemia MF.